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Supplementary Material  
 
Detailed experimental procedures 
 
1. Skin dendritic cell isolation and culture 
Following dispase (2U/ml, Gibco, UK) digestion of epidermal sheets, migratory DCs were harvested after 48 hours culture of epidermal and 
dermal fragments, and immediately cryopreserved in 90% FBS (Invitrogen, UK), 10% DMSO (Sigma, UK). Low density cells were enriched 
using density gradient centrifugation (Optiprep 1:4.2, Axis Shield, Norway (Polak, 2011)) and purified with magnetic beads according to 
manufacturer’s protocol (epidermal cells: CD1a+, dermal cells: CD11c+, Milenyi Biotec, UK). For pulsing with a nominal CD8+ T cell epitope, 
DCs were incubated with 100 M of a HLA-A2 restricted EBV-derived peptide (GLC: GLCTLVAML; Cambridge Peptides, UK) for 18 hours, 
with TNF-α added at 2 hours, and washed thoroughly before co-culture with T cells. For cross-presentation experiments, DCs were pulsed with 
10 M proGLC (FNNFTVSFWLRVPKVSASHLEGLCTLVAML; Peptide Protein Research, Fareham, UK) for 24 hours and supplemented 
with TNF-α after 6 hours (Polak et al., 2012). 
 
2. EBV-peptide specific T cell expansion 
PBMC from HLA-A2 individuals were isolated by Ficoll-Hypaque density gradient centrifugation and co-cultured with 40 μM EBV peptide for 
12 days in complete medium supplemented with 1% sodium pyruvate (Gibco, UK) plus 10% human serum (Sigma,UK). IL-2 (100 IU/ml, 
Peprotech, UK) was added every 3 days. IL-2 was removed from the culture for 24 hours prior to testing in ELISpot. For proliferation assays 
CFSE (Invitrogen, UK) labelled EBV-specific T cells were re-stimulated with GLC pulsed or un-pulsed CD1a+LC or CD11c+ DDC for 7 days. 
Prior to flow cytometric analysis, cells were labelled with CD3-PerCP, CD8-APC antibodies (BD Biosciences UK). IFN-γ release from GLC-
specific T cells was assessed with ELISpot assay (Mabtech, Sweden).  For ELISpot assays, TNF-α matured and washed EBV peptide pulsed 
DCs (1x10
3 
cells) were co-cultured with GLC peptide-specific T cells (5x10
4
 cells/ per well) for 20 hours as per manufacturer’s protocol 
(Mabtech, Sweden). Spot forming units (sfu) were enumerated with ELISpot 3.5 reader. For caveolin-1 blocking assay, cell cultures were 
supplemented with Filipin III (Sigma, UK) at pre-titrated concentrations (1 g/ml and 0.1 g/ml). 
 
 
3. Alignment of T0 migratory cells transcriptome to transcriptomes of cells isolated from the human skin by trypsinisation. 
To test whether the skin migratory LCs and DDCs recapitulate the transcriptome of cells rapidly isolated from skin using trypsinisation protocol 
followed by bead purification, we conducted a whole transcriptome analysis of existing expression datasets. To date, four such studies were 
performed, by Santegoets at al [1], Allen at al [2] Hutter at al [3] and Harman et al [4] (Supplementary Table 2). Data sets for analysis were 
selected based on the following criteria: (i) cell type studied, (ii) microarray genechip platform (Affymetrix human genome expression arrays). 
As outlined in Supplementary Table 3 only datasets from study [1] and [2] were suitable for direct comparison with our data, and only study [1] 
comprised both LCs and DDCs. Raw data (.cel) files from GSE23618 and LC files from GSE16395 and GSE35340 were downloaded and 
normalized using RMA algorithm within the Affymetrix package, annotated, and taken forward for further analysis. Due to the pronounced 
study-related batch effect only LCs and DDCs from GSE23618 were compared directly with our migratory cell dataset, while LCs from the 
study by Allen and colleagues (GSE16395) and Hutter and coleagues (GSE35340) were assayed for the presence of identified gene signatures. 
4. Validation of gene expression differences by qPCR 
RNA was extracted from bead-purified CD1a+ LCs and CD11c+DDCs from three independent skin samples stimulated with TNF-α (Miltenyi 
Biotec, UK, 25 ng/ml) for 0, 2, 8 and 24 hours, using Qiagen pico. The quantity and purity of extracted RNA was assessed using a NanoDrop-
2000 spectrophotometer and the RNA sample concentration was adjusted to 50 ng/l. RNA samples, including RT-negative control, were 
transcribed to cDNA using NanoScript 
TM 
 reverse transcription kit (Primer Design, UK). The RT reaction was carried out in a pre-programmed 
GeneAmp 9700 Applied Biosystems Thermal Cycler (ABI, USA), in a two-step reaction consisting of 5 min at 60C followed by 60 min at 42C. 
PCR was carried out using the TaqMan gene expression assays for target genes: YWHAZ (HS03044281_g1), CAV1 (Hs00971716_m1), 
PSMD14 (Hs01113429_m1), CCL18 (Hs00268113_m1). qPCR was performed in a small volume 384 well plate assay, using Applied 
Biosystems 7900HT Fast Real-Time PCR System.  Gene expression levels were normalised to housekeeping gene expression (YWHAZ), and 
expressed as 2
-dCT 
where dCT = target gene expression level – YWHAZ expression level.  
 Supplementary Figure Legends 
Supplementary Figure 1. 
(a-c) Mean RMA normalised expression (± SEM) expression of HLA class II and transactivator (CIITA) (a), HLA class I and β-2 microglobulin 
(B2M) (b) and key co-stimulatory molecules (c) in 48h migratory human skin derived LCs (black bars) and DDCs (grey bars), n=3 independent 
skin donors in duplicate. No statistically significant differences detected (paired T test, Bonferroni correction).  
Supplementary Figure 2. 
The comparative heat maps of expression levels of the genes of interest (GOI), identified as gene signature in migratory cells at T0 (> 1.5 fold difference in 
log2(x) RMA normalised gene expression levels between the cell types) in migratory (a,c) and trypsinised (b,d) LCs vs DDCs. 100 top GOI up-regulated in 
LC (a,b) and 100 top GOI up-regulated in DDCs (c,d) are shown. Biological processes identified with gene ontology analysis are indicated for the genes 
enriched in LCs and DDCs. 
Supplementary Figure 3. 
(a-c) Mean RMA normalised expression of (a) cytokines (b) chemokines (c) co-stimulatory molecules in in LC (black bars) or DDCs (grey bars) 
during the time course of stimulation with TNF-α as assessed by microarrays, n=3 independent skin donors. 
Supplementary Figure 4. 
(a-e) RMA normalised expression of (a) genes involved in metabolism (b) cytoskeleton reorganisation and signalling (c) proteasome subunits (d-
e) mitochondria associated genes in in LC (black bars) or DDCs (grey bars) during the time course of stimulation with TNF-α as assessed by 
microarrays, n=3 independent skin donors. 
 
  
Table S1.  
  
LC 
Total (higher in LC) 
DDC 
Total (higher in DDC) 
Migratory cells 
(time 0) 969 1,648 
Probesets up-
regulated by TNFa  311 (178) 1,007 (874) 
Probesets down-
regulation by TNFa  201 (128) 1,058 (985) 
 
Table S1. Number of probesets differentially expressed in LCs and DDCs at time 0 and over the time course of stimulation with TNF-α, 
(inclusion criteria: 1.5 fold difference in log2(x) RMA normalised gene expression levels between the cell types (time 0) or between the 
maximum RMA normalised gene expression level over the log2(x) RMA normalised gene expression level at time 0, (for TNF-α regulated genes 
exceeding 0.05 of Bayesian Estimation of Temporal Regulation). 
  
Supplementary Table S2. Gene ontology analysis for genes overexpressed in migratory LCs and DDCs before stimulation with TNF-α. 
LC 
hsa01040: Biosynthesis of unsaturated fatty acids (6.1801) 
hsa00280: Valine, leucine and isoleucine degradation (3.7081) 
hsa04520: Adherens junction (2.8252) 
hsa00640: Propanoate metabolism (4.2488) 
hsa00072: Synthesis and degradation of ketone bodies (9.0642) 
hsa00330: Arginine and proline metabolism (3.0784) 
hsa00071: Fatty acid metabolism (3.3991) 
hsa00512: O-Glycan biosynthesis (3.6257) 
Surface receptors ACVR1, ACVR1C, C21orf63, CALCRL, CD207, CX3CR1, CXADR, CXCR6, GABBR1 / UBD, GPR125, GPR153, 
GPR55, GPR64, HTR2B, LDLR, LSR, P2RX5, S1PR1, TGFBR3, TNFRSF11A, TNFRSF11B, TNFRSF8, TREML1 
Regulators of signal 
transduction 
CHN1, CASP6, AGK, ALPK2, ANXA2, ANXA, APBB1IP, ARHGEF12, ARL2, ASB1, AXIN2, BAIAP2, BMP2K, 
BMPR2, C2orf72, C6orf170, CABYR, CASP3, CDKN2A, CDKN2B, DBI, DEF8, DEPDC6, ECE1, ENSA, FARP1, 
FARP2, FER, FKBP1A, FMOD, GATSL3 /TBC1D10A, GNAI1, GNG11, IGFBPL1, INADL, LANCL1, LANCL2, 
MAP3K6, MNAT1, NXN, PHACTR1, PIK3CG, PPAP2A, PPP1R16B, PPP1R1C, PPP2R3A, PRKAR2B, PRKCZ, 
PTPRK, PTPRM, RAB23, RABGAP1L, RABL3, RABL5, RAD1, RAP1GDS1, RAPGEF4, RARRES3, RHOF, 
RHPN2, RINL, RRAD, RSU1, SCUBE2, SOX4, STAT1, TBC1D4, TBCK, THEMIS, THOP1, TIFAB, WEE1, 
WNT5B, TNFAIP8L3, TRAF5 
Regulators of 
transcription/translation 
ASL, POLR1B, SF3A3, SFPQ, SYNCRIP, TSEN54, PRMT7, ARNT2, BATF, BCL11B, C17orf79, CELF4, ELP3, 
FHL1, FHL2, GTF2H5, HINT2, HMGN3, HOMEZ, IFT57, IKZF2, KDM5B, LMCD1, LZTFL1, MCM2, MEX3D, 
MKL2, MTA3, MTERFD3, MXD4, MYEF2, NUFIP1, OCIAD2, PASK, PBXIP1, PELP1, PHB, PHTF1, REXO2, 
RQCD1, SMARCA1, SMARCE1, SP110, SP140, TAF5L, TAF9B, TCF3, TIGD2, TRIM16, TRIM44, TTF2, ZBED3, 
ZBTB8A, ZC3HC1, ZDHHC16, ZDHHC16, ZG16B, ZMAT3, ZNF195, ZNF260, ZNF268, ZNF287, ZNF362, 
ZNF428, ZNF480, ZNF544, ZNF593, ZNF608, ZNF642, ZNF643, ZNF75A, ZNF789, ZNF880, ZNF93, ZNHIT6, 
ZNRF1, ZSCAN2, CPEB1, CPEB2, DTD1, EBNA1BP2, EIF2AK1, ELAC1, GFM2, HNRNPA3 / HNRNPA3P1, 
IARS, MARS2, NHP2, NOC3L, NPM1, NUP35, PTRH1, FARS2, CDX2, SMARCAD1 
Effectors ABCA10, ABCA3, ABCB10, ABCC4, ABP1, ACACA, ACADVL, ACAT1, ACAT2, ACBD6, ACOT1 / ACOT2, 
ACOT7, ACOX3, ACTB, ACTR3B, ACTR3C, ADAM12, AGA, AGL, AHI1, ALDH18A1, ALDH1B1, ALG2, 
AMIGO2, ANK3, ANKRD36 / ANKRD36B, ANKRD55, AP1S1, AP2B1, APITD1, APOA1BP, APOC1, APOC2, 
APOE, ARL2 /SNX15, ASNS, ATIC, ATOX1, ATP1A4, ATP6V0A2, ATXN10, AVEN, BAG2, BARD1, BCKDHB, 
BDH2 / NHEDC2, BET1, BID, BLMH, BPHL, C10orf35, C11orf2, C11orf41, C14orf1, C14orf126, C14orf145, 
C18orf10, C19orf12, C1orf115, C3, C4orf23, C4orf34, C6orf105, C6orf108, CAPN3, CASQ1, CBS, CCL22, 
CD70, CDC14B, CDCA5, CDH1, CETN2, CFL1, CHI3L1, CHL1, CHST2, CLIC3, CLU, CLUAP1, CNN2, COG5, 
COTL1, CPSF6, CSRP2, CSTA, CTPS, CTTN, CYB561, CYB5R2, CYBASC3, CYFIP2, CYP2U1, DCTPP1, DDA1, 
DDHD2, DENND1A, DENND5B, DFFA, DHCR24, DMD, DNAJC10, DNAJC21, DNAJC30, DPP3, DSP, 
EDEM1, EFNB3, ENO3, EPB41L4A, EPCAM, FAM118A, FAM129A, FAM136A, FAM164A, FAM165B, 
FAM171B, FAM189A1, FAM69A, FANCF, FBXO2, FBXO25, FCGBP, FDPS, FECH, FGGY, FKBP1B, FLOT2, 
FN1, FNBP1L, FSCN1, FUT8, GALK2, GALNT1, GALNT11, GALNTL4, GCNT1, GCNT2, GCSH, GJA1, GLS, 
GNPNAT1, GOT1, GSPT1, HEATR1, HEATR2, HLA-DQA2, HMOX2, HSD17B10, HSD17B8, HSPB11, ICAM4, 
IGSF3, IMPA2, INPP5J, ITGB1BP1, ITIH1, ITM2C, ITPA, KCNMB1, KDELR3, KIF21A, KIF3A, KIF3C, KIF5C, 
KIFAP3, LAMB1, LIMA1, LIMCH1, LLGL2, LMNB1, LOR, LSP1, MAP4, MARVELD2, MCC, MCOLN2, 
MCOLN3, MGMT, MGP, MICAL2, MIPEP, MMAB, MMP13, MOCOS, MOSC2, MRPL1, MRPL11, MRPL24, 
MRPL48, MRPS28, MRPS33, MRPS35, MSH2, MTHFS, MTMR2, MXRA7, MYH9, MYL6B, MYL9, MYO6, 
NAA10, NACAD, NAV1, NDUFB7, NEK1, NFU1, NID2, NOP16, NOS1, NQO1, NRCAM, NRXN2,OTUD7B, 
PALLD,  PCCA, PDLIM3, PECR, PEX11B, PFAS, PFDN6, PFKM, PFN1, PGM2L1, PIGN, PLA2G16, PLEK2, 
PLEKHG1, PLP1, PLS3, PNKD, PNPT1, PON2, PPCDC, PRRT3, PSAT1, PSMC3, PXMP4, QDPR, RAD50, 
RARRES2, RIMS3, S100A13, S100B, SAMM50, SCN4B, SEC11C, SEC22C, SEMA4F, SEPT11, SERF1A / 
SERF1B, SERPINE2, SETMAR, SH3D19, SH3KBP1, SHMT2, SILV, SLAMF7, SLC24A3, SLC25A4, SLC25A43, 
SLC25A46, SLC38A9, SLC39A13, SLC7A6, SLC9A2, SNRNP25, SNX4, SNX7, SPAG16, SPOCK2, SPTBN1, 
SQLE, SRR, SSX2IP, ST8SIA1, STARD9, STOML2, STRBP, SWAP70, SYNPO, SYNPO2, SYT11, TAPBPL, TBCB, 
TBCEL, THBS2, THEM4, TIAM2, TIMM10, TIMM13, TIMM8B, TJP1, TMED4, TMEM110, TMEM136, 
TMEM14A, TMEM14B, TMEM150C, TMEM160, TMEM163, TMEM169, TMEM200A, TMEM97, TMSB15B, 
TOMM34, TP53I3, TPM1, TPM3, TPST1, TRAPPC6A, TRIM32, TRO, TRPC1, SPAN13, TSPAN15, TTPAL, TYR, 
TYRP1, UBE2QL1, UBFD1, UCHL3, UROS, USP46, VCAM1, VPS41, WDR1 
  
DDC 
hsa04060: Cytokine-cytokine receptor interaction (3.0069) 
hsa04062: Chemokine signaling pathway (2.2980) 
hsa04621: NOD-like receptor signaling pathway (5.0827) 
hsa04650: Natural killer cell mediated cytotoxicity (2.2617) 
hsa04142: Lysosome (2.3261) 
hsa04620: Toll-like receptor signaling pathway (2.4110) 
hsa04640: Hematopoietic cell lineage (2.6650) 
hsa04610: Complement and coagulation cascades  (3.1139) 
hsa04670: Leukocyte transendothelial migration (1.6995) 
hsa04666: Fc gamma R-mediated phagocytosis (1.9601) 
hsa04664: Fc epsilon RI signaling pathway (2.2037) 
hsa05322: Systemic lupus erythematosus (1.7362) 
hsa03320: PPAR signaling pathway (2.2835) 
hsa04520: Adherens junction  (1.8603) 
hsa05219: Bladder cancer (2.7284) 
hsa05014: Amyotrophic lateral sclerosis (ALS) (2.1621) 
hsa00590: Arachidonic acid metabolism (2.0463) 
hsa05020: Prion diseases (2.8648) 
hsa00920: Sulfur metabolism (4.7746) 
Surface receptors ACVR1B, ADORA2B, ADORA3, ADRB2, AGTRAP, ASGR1, ASGR2, C3AR1, C5AR1, CD14, CD163, CD163L1, 
CD180, CD209, CD274, CD300A, CD300C, CD300E, CD300LF, CD302, CD33, CD36, CD44, CD48, CD53, 
CD68, CD72, CD82, CD93, CLEC10A, CLEC12A, CLEC1A, CLEC2B, CLEC4A, CLEC4D, CLEC4E, CLEC4G, 
CLEC5A, CLEC7A, CMKLR1, CNRIP1, CRISPLD2, CSF1R, EVI2A, EVI2B, F13A1, FABP4, FCAR, FCER1G, 
FCGR1A, FCGR2A, FCGR3A, FCGRT, FFAR2, FGFR1, FOLR2, FPR1, FPR2, FPR3, GFRA2, GPNMB, 
GPR109A / GPR109B, GPR155, GPR34, GPR68, GPR84, HAVCR2, HBEGF, HEBP1, INSR, ITGAL, ITGAM, 
ITGAX, IVNS1ABP, KIR2DL4 /KIR2DL5A, KLRC1, KLRK, LDLRAD3, LEPR, LGALS8, LILRA2, LILRA3, 
LILRA6, LILRA6 / LILRB3, LILRB1, LILRB2, LILRB4, LILRB5, LPAR2, LPAR6, LYVE1, MARCO, MRC1 
/MRC1L1, MRC1L1, MSR1, NKGC2, OLR1, OSBPL1A, P2RX4, P2RX7, P2RY6, PILRA, PLAUR, PTAFR, 
PTGER2, PTPRE, PTPRJ, RXRA, S1PR2, SCARA5, SCARB2, SCARF1, SIGLEC1, SIGLEC12, SIGLEC14, 
SIGLEC7, SIGLEC9, SORL1, STAB1, SUCNR1, THRB, TLR1, TLR2, TLR4, TLR5, TLR8, TREM1, TNFRSF10A, 
TNFRSF10B, TNFRSF10D, TNFRSF14, TNFRSF21, TNFSF12, TNFSF12-TNFSF13 / TNFSF13, TNFSF15, 
TREM2, VLDLR  
Regulators of 
signal 
transduction 
ABCA1, ADA, ADM, AK4, ANG, AREG, ARHGAP18, ARHGAP19, ARHGAP22, ARHGAP24, ARHGAP26, 
ARHGAP6, ARHGAP9, ARHGEF10L, ATP6AP2, AZI2, C13orf15, C13orf18, C19orf61, CALML4, CAMK2D, 
CARD16, CASP4, CASP5, CDC42EP3, CISH, CLK1, CRIM1, CYTH4, DAPK1, DDIT4, DNMBP, DOK3, DUSP6, 
ECM1, EMR2, EPS8, EREG, F3, FES, FGD3, FGD4, FLT1, GDF15, GEM, GIMAP4, GIMAP5, GIMAP8, 
GNA15, GNG4, GRK5, HCST, HIPK2, HPCAL1, INHBA, INPP4A, INPP5D, IQGAP2, IQSEC1, IRAK3, ITGB2, 
KITLG, KL, LCP2, LPIN1, MAP2K3, MAP3K5, MAPK13, MAPK14, MCTP1, MERTK, MET, MLKL, MOBKL2B, 
MOBKL2C, MRAS, NOTCH2, NDRG1, NRP1, OSM, PAG1, PDE2A, PID1, PIK3AP1, PLAT, PLAU, PNP, 
PPAP2B, PPBP, PPP1R3B, PRKCH, PTP4A3, PTPN6, PYCARD, RAB20, RAB24, RAC2, RALGDS, RASA3, 
RASA4, RBPJ, RCAN1, RGL1, RHOB, RHOH, RHOQ, RHOU, RIN2, RIPK2, RRAGD, SAMHD1, SASH1, SASH3, 
SDC2, SDCBP2, SGK1, SH3BP2, SH3BP5, SH3PXD2B, SIK3, SLA, SLAMF1, SOCS3, SPRED1, STAC, SYK, 
TBC1D2, TESK2, TGM2, THBS1, TIMP2, TK1, TNIK, TNS3, TRAF3IP2, TSPAN4, VSIG4, WSB1 
Transcription regulators AHRR, BACH1, BCL11A, BCLAF1, BHLHE41, BMP6, C11orf30, CBFA2T3, CCNL1, CEBPA, CEBPB, CEBPD, 
CITED2, CREB5, DEDD2, DOT1L, E2F3, EAF1, EGR1, EGR2, EHF, EPAS1, FLI1, FOS, FOSB, FOSL2, 
H3F3B, HIF1A, HIST1H2BN, HOPX, HOXB2, ING2, IRF2BP2, IRF8, JARID2, KLF2, KLF3, KLF9, LRRFIP1, 
MAF, MAFB, MAFF, MAMLD1, MDM4, MITF, MXD1, MYC, NR4A1, NR4A2, NR4A3, NUPR1, PER1, PRDM8, 
RFX8, RUNX1, RUNX2, SAP30, SATB1, SCML1, SMAD3, SNRPG, SSBP2, SSBP3, SSR1, TCF7L2, TFEC, 
TRERF1, TRIM22, TSC22D1, TSC22D3, TSPYL2, TWIST1, TXNIP, VENTX, ZBTB16, ZC3H11A, ZCCHC14, 
ZCCHC2, ZCCHC6, ZEB2, ZFP36L2, ZMYND8, ZNF331, ZNF395, ZNF467, ZNF503, ZNF697, ZNRF2, ZXDC, 
ETS2, ID3, ANKHD1, DMXL2, EIF4G3, RPL37, RPL39L 
Effectors ABCC3, ABCG1, ABHD5, ACSL1, ACSL5, ACTN1, ADAMDEC1, ADARB1, ADSSL1, AIF1, AKR1C1, AKR1C2, 
AKR1C3, ALDH1A1, ALDH3B1, ALOX15B, ALOX5, AMPD3, AMY1A / AMY1B / AMY1C, AMY2B, ANGPTL4, 
ANKH, ANO6, ANPEP, AOAH, APP, AQP9, ARAP1, ARG2, ARID5B, ARSG, ASAH1, ASRGL1, ATG16L2, ATG5, 
ATP13A3, ATP1B1, ATP6V0D2, ATP8B4, AVPI1, B3GALNT1, BCAT1, BCL2L14, BCL6, BEST1, BIN1, BNIP3, 
BNIP3L, BTG1, C1QA, C1QB, C1QC, C6orf192, CA12, CACNA2D3, CACNA2D4, CALCOCO2, CAPN5, CAPN7, 
CARD6, CASP1, CCL13, CCL17, CCL18, CCL19, CCL2, CCL20, CCL3, CCL3L1 / CCL3L3, CCL4 / CCL4L1 / 
CCL4L2, CCL4L1 / CCL4L2, CCL7, CCNE2, CCR1, CCR5, CCRL2, CDH26, CDKN2D, CECR1, CES1, CFD, 
CFLAR, CH25H, CHST15, CIDEB, CLDN23, CLN8, CLPB, CMAH, COLEC12, CPM, CPVL, CRYL1, 
CSGALNACT2, CST3, CTSB, CTSD, CTSK, CTSL1, CXCL1, CXCL12, CXCL13, CXCL2, CXCL3, CXCL5, 
CXCL5 / GLYR1, CXCL6, CXCR7, CYBB, CYP27B1, CYP2R1, DAB2, DHRS9, DLL1, DNER, DOCK2, DPEP2, 
DPYD, DRAM1, DST, EEPD1, EGLN3, EHD1, ELOVL7, EMP1, EPB41L3, ERO1LB, FAH, FAIM3, FBP1, 
FCN1, FKBP15, FMN1, FMNL2, FTH1, FUCA1, FUT11, FXYD5, FZD2, G0S2, GAA, GAS7, GATM, GBGT1, 
GBP2, GBP5, GFOD1, GK, GLRX, GLT25D1, GLT25D2, GLUL, GNLY, GNS, GPCPD1, GPX3, GYPC, 
HERPUD1, HFE, HIP1, HK2, HK3, HNMT, HOMER3, HPSE, HS3ST3B1, HSD11B1, HSPA6, HTRA1, HVCN1, 
IFITM3, IGSF21, IGSF6, IL10, IL15RA, IL17RA, IL18BP, IL18R1, IL18RAP, IL1A, IL1B, IL1R2, IL1RAP, 
IL1RL1, IL1RN, IL24, IL2RA, IL3RA, IL6, IL8, IRS2, ITGB8, JAG1, KCNE1, KCNE3, KCNJ15, KCNK13, 
KCNMA1, KCNN4, KCTD12, LAIR1, LAMB3, LAPTM5, LAT2, LATS2, LGMN, LIPA, NAIP, LPCAT2, LPL, 
LRP1, LTBP2, LY86, LYZ, MAD1L1, MAOA, MARCH1, MFSD1, MGAT4A, MGST1, MICALL2, MKKS, MMP1, 
MMP10, MMP12, MMP19, MMP7, MMP8, MMP9, MPEG1, MPHOSPH6, MT1F, MT2A, MYO7A, MYOF, 
NAMPT, NCEH1, NCF2, NCF4, NDRG1, NDST1, NDUFS2, NEFH, NINJ1, NISCH, NLRC4, NLRP1, NLRP3, 
NOD2, NPC1, NPL, NRIP3, NT5E, NUP214, P4HA1, PAPSS2, PCTP, PDCD1LG2, PDK1, PDK4, PDPN, PDXK, 
PFKFB3, PFKFB4, PFN2, PGCP, PGS1, PLA2G4A, PLIN2, PLSCR1, PLTP, PMP22, POR, PSTPIP1, PTGES, 
PTGS2, PYGL, QKI, QPCT, RNASE4, RNASE6, RNASET2, RNF130, RNF144B, RNF149, RRM2B, S100A12, 
S100A8, S100A9, SBF2, SCCPDH, SEC24A, SECTM1, SEMA4B, SEMA4D, SERINC2, SERPINA1, SERPINB2, 
SERPINB3 / SERPINB4, SERPINE1, SLC11A1, SLC11A2, SLC12A6, SLC16A10, SLC16A6, SLC1A2, SLC1A3, 
SLC22A15, SLC22A4, SLC25A37, SLC26A11, SLC2A14 / SLC2A3, SLC30A1, SLC35B4, SLC36A4, SLC37A2, 
SLC38A6, SLC39A8, SLC7A7, SLC7A8, SLC8A1, SLCO2B1, SLCO4A1, SLITRK4, SMOX, SMPDL3A, SNTB1, 
SNX10, SNX30, SOD2, SPARC, SPOCK1, SPP1, ST3GAL1, ST8SIA4, STARD13, STC1, STEAP3, STEAP4, 
STT3B, SULF2, SYPL1, SYTL3, TAGLN, TBXAS1, TCIRG1, TET2, TFPI, TGFBI, THBD, TKTL1, TMPRSS11E, 
TNF, TNFAIP6, TNNT1, TPCN1, TPST2, TRPM2, TTLL3, TUBA4A, UBAC2, UNC119, UPP1, UTRN, VAMP4, 
VAV3, VCAN, VEGFA, VNN1, VNN2, VNN3, WIPF1, XCL1 /XCL2, YOD1 
 
Supplementary Table S2. Gene ontology analysis for genes overexpressed in migratory LCs and DDCs before stimulation with TNF-α. 
Lists of genes overexpressed in migratory LCs and DDCs (above 1.5 fold difference between the cell types in log2(x) RMA normalised gene 
expression levels) were submitted to gene set enrichment (GSE) analysis was done using ‘‘functional annotation clustering’’ tool, (similarity 
threshold 0.5, multiple linkage threshold 0.5, EASE:1.0 and Benjamini correction) within DAVID web-based tool and mapped over the KEGG 
pathway database. Basing on the functional annotation results genes were classified as “receptors” “regulators of signal transduction” “regulators 
of gene transcription and translation” or “effector”. Gene annotations were confirmed by detailed direct analysis using Gene Expression Atlas 
(http://www.ebi.ac.uk/gxa/). 
Supplementary Table S3. 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S3. Datasets of human skin derived Langerhans cells isolated by trypsinisation available in public domain. 
  
 Study Dataset no LC (no 
datasets) 
CD1a+ DDC 
(no datasets) 
Platform 
[1] Santegoets et al GSE23618 3 3 Affymetrix  HG U133 plus 2 
[2] Allen et al GSE16395 12 0 Affymetrix  HG U133 plus 2 
[3] Hutter et al GSE35340 3 0 Affymetrix  HG U133 plus 2 
[4] Harman et al GSE32648 2 3 Illumina 
GSE32400 4 4 AGRF Human 8K cDNA 
Microarray 
Supplementary Table S4 
Pathways overrepresented in trypsinised DDC Pathways overrepresented in trypsinised LC 
hsa04060:Cytokine-cytokine receptor interaction hsa00240:Pyrimidine metabolism 
hsa04512:ECM-receptor interaction hsa00590:Arachidonic acid metabolism 
hsa04610:Complement and coagulation cascades hsa02010:ABC transporters 
hsa04640:Hematopoietic cell lineage hsa04010:MAPK signaling pathway 
hsa04630:Jak-STAT signaling pathway hsa04110:Cell cycle 
hsa04062:Chemokine signaling pathway hsa04514:Cell adhesion molecules (CAMs) 
hsa04510:Focal adhesion hsa04520:Adherens junction 
hsa04620:Toll-like receptor signaling pathway hsa04540:Gap junction 
hsa04621:NOD-like receptor signaling pathway hsa04810:Regulation of actin cytoskeleton 
hsa05020:Prion diseases hsa04310:Wnt signaling pathway 
hsa04672:Intestinal immune network for IgA production 
GO-Term biological process analysis:  
fatty acid metabolic process, prostaglandin metabolic process, 
carbohydrate metabolism, ubiquitine-mediated proteolysis 
hsa03320:PPAR signaling pathway 
hsa04514:Cell adhesion molecules (CAMs) 
hsa04650:Natural killer cell mediated cytotoxicity 
hsa05200:Pathways in cancer 
hsa04623:Cytosolic DNA-sensing pathway   
hsa04360:Axon guidance   
hsa05222:Small cell lung cancer   
hsa00561:Glycerolipid metabolism   
hsa00010:Glycolysis / Gluconeogenesis   
hsa03320:PPAR signaling pathway   
hsa00770:Pantothenate and CoA biosynthesis   
hsa00230:Purine metabolism   
 
Supplementary Table S4. DAVID functional gene classification and functional annotation of genes  overexpressed in trypsinised LCs 
and trypsinised DDCs  
Gene lists of 742 transcripts  (516 genes) preferentially expressed in trypsinised LC, and 1268 transcripts (804 genes) preferentially expressed in 
DDCs (> 1.5 fold difference in log2(x) RMA normalised gene expression levels between the cell types, GSE23618) were submitted to DAVID 
functional classification and annotation to identify biological processes overrepresented in each cell type. 
 
Supplementary Table S5. 
 
Genes 
preferentially 
regulated in 
DDCs 
(ANOVA)* 
Peak of 
expression 
[hours] 
Number 
of 
probesets 
Over-represented 
processes and cell 
compartments 
Examples of genes in the cluster 
Cluster 01 
(p<0.0001) 
0h 760 Immune response 
Surface receptors 
Phagocytosis 
ADAM28, CD163, CD180, CD209,CD36, CD274, CLEC1A, CLEC4G, 
CLEC5A, CLEC7A, CXCL2, CXCR7, FCGR2A, FCGR2B, FCGR3A, 
IL1R2, IFR2BP, IRF3, IRF4, ITGAM, ITGB2, MSR1, THBS1 (CD141), 
TLR2, TLR4, TLR5, TNFSF12, TNFSF13 
Cluster 02 
(p=0.0001) 
2h 293 Transcription 
Immune response 
Signal transduction 
regulation 
E2F6, EIF2C2,EIF4A3, EIF4E, EIF5, GPR109A, GPR18, GPRC5A, 
CREM, RPL28,  TNFRSF10D, TNFRSF 12A, TNFSF14, TNFSF15, TNF, 
IL7, IL1RN, CXCR4, CCL3, CCL4, DYRK-3, RIPK1, MAPK2K3, 
PPP1R10, PPM1D, ZNF36, ZNF295, ZNF 331, ZNF697, ZNF703 
Cluster 04 
(p<0.0001) 
8h 172 Oxidative stress 
response 
Sphingiolipid 
metabolism, 
Lysosome activity, 
Immune response 
AKR1C3, PTGER2,  CYP1B1, CYP7B1,  SOD2, ITGB8, SNX10, IL1A, 
IL23A, MT1H 
Cluster 06 
(p<0.0001) 
24h 105 Immune signalling 
Cytokine secretion 
Chemokine activity 
Rearrangement of 
extracellular matrix 
Regulation of cell 
migration 
CYBB, CYP27A1A, CCL1, CCL2, CCL17, CCL18, CCL24,CD44, CD82, 
CLEC4D, CLEC4E, CXCL1, CXCL6, GPR68, IFNAR1, IL10,IL1B, 
ITGB3, ITGB8, MMP1, MMP7,MMP9, MMP14, PDPN 
Cluster 07 
(p<0.0001) 
8h 61 Immune response 
Macromolecule 
metabolism 
CD109,IFI44, IFIT1, IFIT3, LRP12,MT1G, MT1X, MX1, MX2, PTGER3, 
TNFSF13B 
AKR1C1, ADA, OAS1 
Cluster 08 
(p<0.0001) 
0h 56 Immune response 
Surface receptors 
Ion channel function 
CD14, CD33, DPYD, GIMAP4, IL15RA, LAIR1, TLR8, KCTD12 
Cluster 09 
(p<0.005) 
8h 32 Cell homeostasis 
Cellular transport 
ANXA5, GCLC, GCLM, TXNRD1, PTGER3, DDX39, TNPO1 
Genes 
preferentially 
regulated in 
LCs 
(ANOVA)* 
    
Cluster 03 
(p=0.0001) 
24h 208 Mitochondrial activity 
Ribosomal activity 
Response to 
hormones/nutrients, 
Proteasome assembly 
and function, Cell 
MRLP11, MRLP15, MRLP23,MRLP24,MRLP27, MRLP3, MRLP48, 
MRPS28, MRPS35,MRPS7, NDUFA9, NDUFAF4, GLRX3, ACAT1, 
CYB561, DBI, ENSA, PSMA3, PSMB7, PSMD14, PSME3, SNN, IL15, 
CCL22, WNT5B 
cycle 
Cluster 05 
(p<0.0001) 
T0 105 Organisation of 
cytoskeleton, 
Macromolecule 
metabolism 
Carbohydrate 
metabolism 
Mitochondrial 
processes 
ACOT7, VCAM-1, DSP, GSN, EPCAM, IDH2, GALC,  PC, SCD, OXNAD, 
TRAF5, SCN4B, SQLE, UBA5, CIITA, PI3CG, 
Cluster 10 
(p<0.0001) 
2h 27 Regulation of 
transcription 
Intracellular transport 
DENND4A, RFX2, RAB11FIP1 
Cluster 12 
(p<0.0001) 
24h 24 Metal Ion binding, 
Intracellular transport, 
ROS scavenging 
PTGER4, SESN3, SNN,SNX11,SOCS1, SYNPO2,TRAF1, 
Cluster 13 
(p<0.0001) 
2h 23 Regulation of 
transcription 
Metal ion binding 
KLF7,PDLIM1, RHOV, TBCEL 
Cluster 14 
(p<0.0001) 
24h 21 Endocytosis, 
Cytoskeleton 
reorganisation, Signal 
transduction 
CAV-1, SSPN, SYNPO, PTPRK, 
 
Supplementary Table S5. Cluster analysis of gene expression changes in CD1a+ LCs and CD11c+ DDCs activated with TNF-α over 24h.  
Biological processes over-represented in 14 biggest clusters of genes identified with BioLayout Express
3D
 network analysis (r=0.85, MCL=1.7, 
2,334 probesets differentially regulated by TNF-α, Bayesian Estimation of Temporal Regulation) were categorised using ‘‘functional annotation 
clustering’’ tool, (similarity threshold 0.5, multiple linkage threshold 0.5, EASE:1.0 and Benjamini correction) from DAVID web-based tool. * p 
values indicate the statistical difference for LCs and DDCs average gene expression profiles across the time course of stimulation with TNF-α 
were compared with two-way repeated ANOVA for each cluster separately (Bonferroni correction, GraphPad Prism, USA). 
Supplementary Figure 1. 
(a-c) Mean RMA normalised expression (± SEM) expression of HLA class II and 
transactivator (CIITA) (a), HLA class I and β-2 microglobulin (B2M) (b) and key co-
stimulatory molecules (c) in migratory human skin derived LCs (black bars) and DDCs (grey 
bars), n=3 independent skin donors in duplicate. No statistically significant differences 
detected (paired T test, Bonferroni correction).  
Supplementary Figure 2. 
The comparative heat maps of expression levels of the genes of interest (GOI), 
identified as gene signature in migratory cells at T0 (> 1.5 fold difference in log2(x) RMA 
normalised gene expression levels between the cell types) in migratory (a,c) and 
trypsinised (b,d) LCs vs DDCs. 100 top GOI up-regulated in LC (a,b) and 100 top GOI up-
regulated in DDCs (c,d) are shown. Biological processes identified with gene ontology 
analysis are indicated for the genes enriched in LCs and DDCs. 
Supplementary Figure 3. 
(a-c) Mean RMA normalised expression of (a) cytokines (b) chemokines (c) co-stimulatory 
molecules in in LCs (black bars) or DDCs (grey bars) during the time course of stimulation 
with TNF-α as assessed by microarrays, n=3 independent skin donors. 
Supplementary Figure 4. 
(a-e) RMA normalised expression of (a) genes involved in metabolism (b) cytoskeleton 
reorganisation and signalling (c) proteasome subunits (d-e) mitochondria associated genes in 
in LCs (black bars) or DDCs (grey bars) during the time course of stimulation with TNF-α as 
assessed by microarrays, n=3 independent skin donors. 
